Exhibit 10.213

|             |  |                 
|------------ |  | ----------------
|CONFIDENTIAL |  | REDACTED VERSION

[***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN  OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH  RESPECT TO THE OMITTED PORTIONS.    FDA COMPLIANCE
AGREEMENT

This FDA Compliance Agreement (the"Agreement") is made and entered into as of June 12, 2003
("Date of Agreement"), by and between:

Chiron S.r.l, having its registered office at Via Fiorentina 1, 53100 Siena, Italy;

and

Chiron Behring GmbH & Co, with its registered offices at Emil von Behring Strasse 76, 35041 Marburg, Germany, together with Chiron
S.r.l., hereafter referred to as "Chiron";

and

SynCo Bio Partners B.V., having its registered office at Paasheuvelweg 30, 1105 BJ Amsterdam-Zuidoost, The Netherlands, hereinafter
referred to as: "SynCo";

WHEREAS:

---

NOW
THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS:

Adjustments to Plant

Contribution by Chiron and Payment thereof

2

---



FDA Approval Chiron's Responsibility; No Guarantee SynCo

Entire Agreement

Amendments in Writing

Law and Arbitration

Independent Status of Parties.

No Transfer of Rights or Obligations

3

---



Press Release

IN
WITNESS WHEREOF, the Chiron S.r.l., Chiron GmbH & Co and SynCo have caused this Agreement to be executed by their duly authorized representatives:

|Chiron S.r.l.:                                         |  | SynCo Bio Partners B.V.:                           
|------------------------------------------------------ |  | ---------------------------------------------------
|/s/JOHN LAMBERTJohn Lambert President, Chiron Vaccines |  | /s/MIC N. HAMERSDr. Mic N. Hamers Managing Director
|Chiron Behring GmbH & Co:                              |  |                                                    
|/s/JOHN LAMBERTJohn Lambert President, Chiron Vaccines |  |                                                    

4

---

APPENDIX A    Planned and Agreed Adjustments to the Plant required for FDA Licensure

Objectives

The realisation of improvements to Synco's facility at Paasheuvelweg 30 in Amsterdam-Zuidoost (the "Plant") that that are required to be made for the approval of
the Plant by the US Food and Drug
Administration ("FDA") in respect of the registration and launch of Chiron's Menjugate in the United States of America.

Scope

In addition to the activities detailed below the agreed adjustments to the Plant shall be considered to include the activities and all necessary, validation,
qualification and documentation activities required to support FDA licensure of the Plant. Including other activities required of Synco: (i) regarding the preparation of the registration
dossier, (ii) resulting from the pre-approval inspection and (iii) regarding all other activities required to allow the licensing of the Plant by the FDA. The activities are
not considered to include the performance of, or documentation of, any process and cleaning validations related to the manufacturing of Chiron's MenC and CRM197.

The
following adjustments which will be will be executed in the first phase of adjustments ("Phase 1")

The
following adjustments will be will be executed in the second phase of adjustments ("Phase 2")

Planned Timing

"Phase 1" of the adjustments to the facility will be executed[***]. The validation of
these adjustments, including all relevant IQ, OQ and PQ reports is planned to be completed within[***].

"Phase
2" of the adjustments to the facility will be executed during[***]. The validation of these adjustments,
including all relevant IQ, OQ and PQ reports is planned to be completed by[***].

5

---

APPENDIX B    Agreed Payment Milestones

The total amount of[***]will be paid as follows subject to the terms of the FDA
Compliance Agreement:

[***].

[***].

[***].

[***].

[***].

[***].

[***].

Payment
shall be made by Chiron within thirty (30) days from receipt of the relevant invoice following the agreement of the milestone.

[***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN  OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH  RESPECT TO THE OMITTED PORTIONS.

6

---

QuickLinks